Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
TEST:
Myriad myChoice® CDx
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Myriad Genetics
Type:
FDA Approved
Related tests:
‹
BRACAnalysis CDx™ (28)
COLARIS AP®
COLARIS®
Counsyl Reliant™ Cancer Screen
EndoPredict®
Myriad myChoice® CDx Plus
Myriad myRisk® Hereditary Cancer
PANEXIA™
Precise™ Liquid
Precise™ MRD
Precise™ Tumor Molecular Profile Test
Prolaris®
myPath Melanoma
BRACAnalysis CDx™ (28)
COLARIS AP®
COLARIS®
Counsyl Reliant™ Cancer Screen
EndoPredict®
Myriad myChoice® CDx Plus
Myriad myRisk® Hereditary Cancer
PANEXIA™
Precise™ Liquid
Precise™ MRD
Precise™ Tumor Molecular Profile Test
Prolaris®
myPath Melanoma
›
Details
Evidence
News
Search handles
Search handles
Filter by
Latest
over1year
MyChoice CDx examines ovarian cancer tumors using two individual methods (BRCA1/2 mutation and genomic instability) to determine a patients HRD staus. ()
over 1 year ago
Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Myriad myChoice® CDx
over6years
"Our research partners @myriadgenetics and @AstraZeneca are teaming up to use myChoice® HRD Plus to identify advanced #ovariancancer patients that can benefit from Lynparza and Avastin! #knowovarian https://t.co/oBKVRsxJTQ" (@NOCC_National)
over 6 years ago
Clinical
|
Myriad myChoice® CDx
|
Avastin (bevacizumab) • Lynparza (olaparib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login